Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Novo Nordisk reprimanded for allegedly failing to disclose payments - The manufacturer of the weight loss jab Wegovy said it ...

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

Semaglutide, the drug sold as Wegovy for weight-loss and Ozempic for diabetes, is still currently in shortage in the U.S. according to the Food and Drug Administration. Novo Nordisk has committed ...

BURLINGAME, CA, UNITED STATES, February 5, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of extensive research and analysis conducted by our team of experienced market ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk NVO is scheduled to report fourth ... Notably, semaglutide, a GLP-1 agonist, is approved as an Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and as ...

Recently, the Centers for Medicare & Medicaid Services (CMS) included Novo Nordisk’s key GLP-1 drugs, Ozempic and Wegovy, in its list of 15 drugs for Medicare price negotiations. This announcement ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease.

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression. According to ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with ...